Outcome of gastric cancer in the elderly: a population-based evaluation of the Munich Cancer Registry

Abstract

Background Gastric cancer accounts for 5 % of cancer deaths. Proportions of older stomach cancer patients are increasing. Despite the still poor prognosis, standardised treatment has achieved improvements; nonetheless it is questionable whether all age groups have benefitted. Age and outcome need to be examined in a population-based setting. Methods Analyses included Munich Cancer Registry (MCR) data from 8601 invasive gastric cancer patients, diagnosed between 1998 and 2012. Tumour and therapy characteristics and outcome were analysed by two age groups (\70 vs. C70 years). Survival was analysed using the Kaplan-Meier method and relative survival was computed as an estimation for cancer-specific survival.Additional landmark analyses were conducted by calculating conditional survival of patients who survived more than 6 months. Results Fifty-nine per cent of the cohort were C70 years old. These patients had tumours with a slightly better prognosis and were treated with less radical surgery and adjuvant therapy than younger patients. The 5-year relative survival was 40 % for the youngest (\50 years) and 23 % for the oldest patients (C80 years). Survival differences were diminished or eliminated after landmark analyses:The 5-year relative survival in age groups 50-59, 60-69 and 70-79 years was comparable (between 48 and 49.6 %) and slightly worse in the youngest and oldest (45 %), which may be explained by more aggressive tumours and effects of cellular senescence, respectively. Conclusion 123Gastric Cancer (2016( ) 19:713-722 DOI 10.1007 resection and chemotherapy, it is conducted and the result is comparable between age groups.

CXCR6 predicts poor prognosis in gastric cancer and promotes tumor metastasis through epithelial-mesenchymal transition

“…The death rate for GC is next to lung cancer, and the number of deaths caused by GC ranks third in men and fourth in women among total cancer-related deaths (1,2). Accurate figures vary in regards to different populations and world regions (3,4). Despite the declining morbidity and improved standardized treatment, GC carries a poor prognosis with the mortality-to-incidence ratio ranging from 0.35 to 0.8 (5).…”

A population-based study on incidence rates, Lauren distribution, stage distribution, treatment, and long-term outcomes for gastric adenocarcinoma in Central Norway 2001–2011

“…They are inherently highly selected, and reported outcomes are influenced accordingly. Population-based studies that include all patients, irrespective of age, disease stage or treatment are few, to some extent incomplete, and seldom report on individual patient data [3][4][5][6][7].…”

Association of thymidylate synthase expression and clinical outcomes of gastric cancer patients treated with fluoropyrimidine-based chemotherapy: a meta-analysis

“…To our knowledge, survival of GC patients who underwent radical surgery is determined by many clinical aspects including patients’ other primary diseases, TNM stages, operation approaches, and adjuvant or neoadjuvant chemotherapy regimens. 39 , 40 Thus, confounding factors that could not be extracted from the original studies may exacerbate inconsistent results in the adjuvant setting.…”